(Eh) y metanólico (Em) de Pera distichophylla sobre un aislado de ...
(Eh) y metanólico (Em) de Pera distichophylla sobre un aislado de ...
(Eh) y metanólico (Em) de Pera distichophylla sobre un aislado de ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Obtener diferencias estadísticamente significativas<br />
en los valores <strong>de</strong> CI 50 para ambos estadios parasitarios<br />
y para ambos fármacos es <strong>un</strong> resultado imprevisible.<br />
Por tal motivo, se hace necesario ampliar<br />
el número <strong>de</strong> <strong>aislado</strong> orales <strong>de</strong> este mismo brote y<br />
realizar estudios in vitro a estos dos fármacos con el<br />
fin <strong>de</strong> aclarar si la explicación <strong>de</strong> la falla terapéutica<br />
en alg<strong>un</strong>os pacientes venezolanos con ECh pudiese<br />
<strong>de</strong>berse a diferencias en los <strong>aislado</strong>s parasitarios.<br />
REFERENCIAS<br />
1. ALARCÓN DE NOYA B, DÍAZ-BELLO Z, COLME-<br />
NARES C, et al. 2010. Large urban outbreak of orally<br />
acquired acute Chagas disease at a school in Caracas,<br />
Venezuela. J Infect Dis 201:1308-1315.<br />
2. ALZAMORA L, COLONA E, ACERO DE MESA N,<br />
et al. 2007. Efecto citotóxico <strong>de</strong>l extracto metanólico<br />
<strong>de</strong> tres ecotipos <strong>de</strong> Lepidium peruvianum chacon <strong>sobre</strong><br />
líneas celulares HeLa , HT-29. Rev peru biol 13: 219-<br />
222.<br />
3. BAHIA-OLIVEIRA LM, GOMES JA, CANÇADO<br />
JR, et al. 1999. Imm<strong>un</strong>ological and clinical evaluation<br />
of chagasic patients sub-jected to chemotherapy during<br />
the acute phase of Trypanosoma cruzi infection 14-30<br />
years ago. J Infect Dis 182: 634-638.<br />
4. BRENER Z. 1987. Laboratory-acquired Chagas disease<br />
comment (letter). Trans. R. Soc. Trop. Med. Hyg<br />
81:527.<br />
5. CABRERA AL, DE LEÓN MP, MARROQUÍN LA,<br />
CASTRO J, MATTA V. 2004. Susceptibilidad <strong>de</strong> aislamientos<br />
<strong>de</strong> Trypanosoma cruzi, obtenidos en Guatemala<br />
a diferentes tripanocidas. DIGI - USAC: 95-100.<br />
6. CANÇADO JR. 1999. Criteria of Chagas disease cure.<br />
Mem Inst Oswaldo Cruz 94: 331-335.<br />
7. CANÇADO JR. 2002. Long term evaluation of etiological<br />
treatment of Chagas disease with benznidazole.<br />
Rev Inst Med Trop Sao Paulo 44: 29-37.<br />
8. CARRANZA JC, VALADARES HM, D’AVILA DA, et<br />
al. 2009. Trypanosoma cruzi maxicircle heterogeneity<br />
in Chagas disease patients from Brazil. Int J Parasitol<br />
39:963-973.<br />
9. CASTRO JA, DE MECCA MM, BARTEL LC. 2006.<br />
Toxic si<strong>de</strong> effects of drugs used to treat Chagas’ disease<br />
(American trypanosomiasis). Hum Exp Toxicol 8: 471-<br />
479.<br />
10. COURA JR, DE CASTRO SL. 2002. A critical review<br />
on Chagas disease chemotherapy. Mem Inst Oswaldo<br />
Cruz 97: 3-24.<br />
11. COURA JR. 2007. Chagas disease: what is known<br />
and what is nee<strong>de</strong>d - A backgro<strong>un</strong>d article. Mem. Inst.<br />
Oswaldo Cruz 102: 113-122.<br />
12. SCHOFIELD CJ, JANNIN J, SALVATELLA R. 2006.<br />
The future of Chagas disease control. Trends Parasitol<br />
22: 583-588.<br />
13. DE CASTRO S, Y DE MEIRELLES M. 1987. Effects<br />
of drugs on Trypanosoma cruzi and on its interaction<br />
with heart muscle cell “in vitro”. Mem. Inst Oswaldo<br />
Rev. Ibero-Latinoam. Parasitol. (2012); 71 (1): 14-22<br />
SUSCEPTIBILIDAD IN VITRO T. CRUZI ISOLATES FROM VENEZUELA<br />
Cruz 82: 209-218.<br />
14. DE CASTRO SL, MEIRELES M. 1990. Mechanism of<br />
action of a nitroimidazole-thiadiazole <strong>de</strong>rivative upon<br />
Trypanosoma cruzi tissue culture amastigotes. Mem<br />
Inst Oswaldo Cruz 85: 95-99.<br />
15. DIAS GONTIJO E, GALVÃO L, ELOI-SANTOS S.<br />
1999. Chagas Disease: Criteria of Cure and Prognosis.<br />
Mem. Inst. Oswaldo Cruz 94: 357-362.<br />
16. DIAS JCP. 2006. The treatment of Chagas disease<br />
(South American trypanosomiasis). Ann Int Med 144:<br />
772-774.<br />
17. FRANCO-PAREDES C, VON A, HIDRON A, et al.<br />
2007. Chagas disease: an impediment in achieving<br />
the Millennium Development Goals in Latin America.<br />
BMC Int Health Hum Rights 7: 7.<br />
18. FILARDÍ LS, Y BRENER Z. 1984. A rapid method<br />
for testing in vivo the susceptibility of different strains<br />
of Trypanosoma cruzi to active of chemotherapeutic<br />
agents. Mem. Inst. Oswaldo Cruz 79: 221-225.<br />
19. FILARDI LS, BRENER Z. 1987. Susceptibility and<br />
natural resistance of Trypanosoma cruzi strains to drugs<br />
used clinically in Chagas disease. Trans R Soc Trop<br />
Med Hyg 81: 755-759.<br />
20. JANNIN J, VILLA L. 2007. An overview of Chagas<br />
disease treatment. Mem Inst Oswaldo Cruz 102: 95-97.<br />
21. LUNA KP, HERNáNDEZ IP, RUEDA CM, ZORRO<br />
MM, CROFT SL, ESCOBAR P. 2009. In vitro susceptibility<br />
of Trypanosoma cruzi strains from Santan<strong>de</strong>r,<br />
Colombia, to hexa<strong>de</strong>cylphosphocholine (miltefosine),<br />
nifurtimox and benznidazole. Biomédica 29: 448-455.<br />
22. MARTÍNEZ R. 1996. Variabilidad intra-específica en<br />
Trypanosoma cruzi y ensayos <strong>de</strong> Nuevos métodos <strong>de</strong><br />
cribado farmacológico. Tesis Doctoral, Universidad<br />
Complutense <strong>de</strong> Madrid.<br />
23. MAYA JD, REPETTO Y, AGOSIN M, et al. 1997.<br />
Effects of nifurtimox and benznidazole upon glutathione<br />
and trypanothione content in epimastigote, trypomastigote<br />
and amastigote forms of Trypanosoma cruzi.<br />
Mol Biochem Parasitol 86: 101-106.<br />
24. MAYA JD, RODRÍGUEZ A, PINO L, et al. 2004.<br />
Effects of buthionine sulfoximine nifurtimox and<br />
benznidazole upon trypanothione and metallothionein<br />
proteins in Trypanosoma cruzi. Biol Res 37: 61-69.<br />
25. MORENO M, D’áVILA DA, SILVA M, et al. 2010.<br />
Trypanosoma cruzi benznidazole susceptibility in vitro<br />
does not predict the therapeutic outcome of human<br />
Chagas disease. Mem Inst Oswaldo Cruz 105: 918-924.<br />
26. MORELLO A, LIPCHENCA I, CASSELS BK, SPEIS-<br />
KY H, ALDUNATE J, REPETTO Y. 1994. Trypanocidal<br />
effect of boldine and related alkaloids upon several<br />
strains of Trypanosoma cruzi. Comp Biochem Physiol<br />
Pharmacol Toxicol Endocrinol 107: 367-371.<br />
27. MURTA SM, GAZZINELLI RT, BRENER Z, RO-<br />
MANHA AJ. 1998. Molecular characterization of susceptible<br />
and naturally resistant strains of Trypanosoma<br />
cruzi to benznidazole and nifurtimox. Mol Biochem<br />
Parasitol 93: 203-214.<br />
28. NÓBREGA A, GARCÍA M, TATTO E, OBARA M,<br />
COSTA E, SOBEL J, ARAUJO W. 2010. Oral Transmission<br />
of Chagas Disease by Consumption of Açaí<br />
Palm Fruit, Brazil. <strong>Em</strong>erging Infectious Diseases 15:<br />
653-655.<br />
29. RASSI A, LUQUETTI AO. 1992. Therapy of Chagas<br />
21